Board of Directors
Read more:
Board of Directors
Thomas Eldered
Born 1960
Chairman of the board since 2026, board member since 2021
Member of the audit committee
EDUCATION AND TRAINING:
Master of Science in Industrial Economics, Linköpings tekniska högskola
MAIN EXPERIENCE:
Thomas Eldered is co-founder of Recipharm AB where he also worked as CEO between 2008–2021. Prior to that, Thomas was Vice President of Recip AB and Factory Manager for Pharmacia. Thomas has also held various assignments as chairman of the board, board member or deputy board member in companies primarily in the life science sector.
OTHER APPOINTMENTS:
Chairman of the board of Flerie AB, North X Biologics AB, Bonsai Biotherapeutics AB and Amarna Therapeutics BV. Board member of Flerie International AB, Chromafora AB, Bohus Biotech AB, Xintela AB (publ), Kahr Medical Ltd, Prokarium Ltd, Cordivest AB, Pingvinen Penningplacering AB, T&M Förvaltning AB, and T&M Participation AB. Deputy board member of Flerie Invest AB.
TOTAL HOLDINGS (OWN AND RELATED PARTIES): 163,358,321 shares through Flerie Invest AB.
Independent in relation to company and company management: Yes
Independent in relation to primary owners: No
Mattias Bengtsson
Born 1969
Board member since 2019
Member of the remuneration committee
EDUCATION AND TRAINING:
Master of Science in Chemical Engineering at Chalmers University of Technology in Gothenburg, MBA at University of Gothenburg School of Business
MAIN EXPERIENCE:
Mattias Bengtsson has more than 20 years of experience from the chemical and life science industry. He has held senior positions within AkzoNobel, more specifically in industrial purification of pharmaceuticals, for example as General Manager Kromasil and Fine Chemicals, Global Sales and Marketing Manager, Manufacturing Manager and Product Category Manager. In addition, Mattias has held several positions in process chemistry at AstraZeneca in Södertälje.
OTHER APPOINTMENTS:
Business Unit Manager BioMedical & Research, AddLife AB. Chairman of the board of Bergman Labora AB, LabRobot Products AB, BioCat GmbH, BioConnect, and Biolin Scientific AB. Board member of Holm&Halby AS and EuroClone Spa.
TOTAL HOLDINGS (OWN AND RELATED PARTIES): 470,400 shares.
Independent in relation to company and company management: Yes
Independent in relation to primary owners: Yes
Erik Haeffler
Born 1967
Board member since 2026
EDUCATION:
Bachelor’s degree in chemistry and microbiology from Stockholm University
MAIN EXPERIENCE:
Erik Haeffler is the CEO of APL (Apotek Produktion & Laboratorier AB) – one of Europe’s largest manufacturers of extemporaneous medicines and a leading contract manufacturer within the life science sector – and was previously Vice President Manufacturing Services & Head of Sustainability at Recipharm. Before that, Erik Haeffler held various positions within Supply Chain and Production, at AstraZeneca and Meda.
OTHER ASSIGNEMENTS:
Board member of APL Strängnäs AB, APL Fastigheter AB, APL Strängnäs Fastighets AB and Runstenen AB. CEO and board member of Conveija AB.
TOTAL HOLDINGS (OWN AND RELATED PARTIES): 162,462 shares
Independent in relation to company and company management: Yes
Independent in relation to primary owners: Yes
Mark Quick
Born 1966
Board member since 2026
EDUCATION:
First degree in Industrial Studies from Nottingham Trent University and an MBA from the Open Business School
MAIN EXPERIENCE:
Mark Quick is a partner at Flerie AB having previously worked at Recipharm where he was Head of Corporate Development leading the M&A activities. Prior to that he held positions in ICI, Medeva, Celltech and UCB in various business development and supply chain roles.
ANDRA UPPDRAG:
Board member of, amongst others, Bohus BioTech AB, Symcel AB, Empros Pharma AB, Bohus BidCo AB and AnaCardio AB.
TOTAL HOLDINGS (OWN AND RELATED PARTIES): Indirectly 163,358,321 shares through his partnership in Flerie
Independent in relation to company and company management: Yes
Independent in relation to primary owners: No
Gisela Sitbon
Born 1958
Board member since 2012
Chairman of the remuneration committee, member of the audit committee
EDUCATION AND TRAINING:
PhD in Medical Sciences from the Karolinska Institute in Solna
MAIN EXPERIENCE:
Gisela Sitbon has over 25 years of experience from the life science industry, of which more than ten years in senior positions (including CEO) at Professional Genetics Laboratory AB and five years as section manager at Karo Bio AB.
OTHER APPOINTMENTS:
Active as business coach within the life science sector. Chairman of the board of Gradientech AB, Emplicure AB, Emplicure Consumer AB and Emplicure Pharma AB. Board member of Uppsala Universitet Invest AB, Thioredoxin Systems AB, and Sitbon Bioscience Partner Zenz AB.
TOTAL HOLDINGS (OWN AND RELATED PARTIES): 360,002 shares held privately and through the company Sitbon Bioscience Partner Zenz AB.
Independent in relation to company and company management: Yes
Independent in relation to primary owners: Yes
Lena Torlegård
Born 1963
Board member since 2014
Chairman of the audit committee
EDUCATION AND TRAINING:
Bachelor of Science in Business Administration from the Stockholm School of Economics
MAIN EXPERIENCE:
Lena Torlegård has over 20 years of experience as a communications consultant for a large number of companies, including companies in the life science industry. Lena works through Lena Torlegård AB as an independent advisor in financial and corporate communication with several customers in the life science sector.
OTHER APPOINTMENTS:
Communications consultant at Lena Torlegård AB.
TOTAL HOLDINGS (OWN AND RELATED PARTIES): 168,704 shares.
Independent in relation to company and company management: Yes
Independent in relation to primary owners: Yes
Jeremie Trochu
Born 1981
Board member since 2026
EDUCATION: Master’s degree in Business Administration from EMLyon, France.
MAIN EXPERIENCE: Jeremie Trochu has extensive knowledge in the life sciences sector and CDMO industry, with 20 years of experience in successfully building and growing companies globally and leading large-scale transformations. Jeremie was previously part of the team that helped transform Catalent from a private equity spin-off to a publicly traded global CDMO and during his tenure there, he built and operated new businesses in both small and large molecule development and analysis markets, as well as leading successful acquisitions and integration of multiple companies.
OTHER ASSIGNMENTS: CEO of Ardena Holding N.V.
TOTAL SHAREHOLDINGS (OWN AND RELATED PARTIES): –
Independence to the company and the company’s management: Yes
Independence to the main owners: Yes